# Clinical Trials in Longevity & Aging Research

> Last updated: February 2025
> Scope: Comprehensive catalog of clinical trials targeting aging biology, senescence, NAD+ metabolism, mTOR inhibition, senolytics, and related longevity interventions.

---

## Table of Contents

1. [mTOR Inhibitors (Rapamycin / Rapalogs)](#1-mtor-inhibitors-rapamycin--rapalogs)
2. [Metformin](#2-metformin)
3. [Senolytics (Dasatinib + Quercetin)](#3-senolytics-dasatinib--quercetin)
4. [Senolytics (Fisetin)](#4-senolytics-fisetin)
5. [Senescence-Targeting Therapeutics (Other)](#5-senescence-targeting-therapeutics-other)
6. [NAD+ Precursors (NR / NMN)](#6-nad-precursors-nr--nmn)
7. [Alpha-Ketoglutarate (AKG)](#7-alpha-ketoglutarate-akg)
8. [Spermidine](#8-spermidine)
9. [Urolithin A (Mitopure)](#9-urolithin-a-mitopure)
10. [Mitochondrial-Targeted Peptides](#10-mitochondrial-targeted-peptides)
11. [GLP-1 Receptor Agonists (Aging-Relevant)](#11-glp-1-receptor-agonists-aging-relevant)
12. [Gene Therapy for Aging](#12-gene-therapy-for-aging)
13. [Master Summary Table](#13-master-summary-table)

---

## 1. mTOR Inhibitors (Rapamycin / Rapalogs)

### 1.1 PEARL Trial

| Field | Details |
|-------|---------|
| **NCT Number** | NCT04488601 |
| **Trial Name** | PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) |
| **Sponsor** | AgelessRx |
| **Phase** | Phase 2 |
| **Status** | Completed |
| **Intervention** | Rapamycin (sirolimus), low-dose (5mg or 10mg weekly), 48 weeks |
| **Population** | 114 healthy adults aged 50-85 |
| **Key Endpoints** | Visceral fat, lean body mass, bone density, epigenetic age |
| **Results** | Lean mass improved in women (10mg group); reduced pain; improved emotional well-being and general health (5mg group). Safe and well-tolerated overall. Important note: compounded rapamycin had approximately 1/3 concentration of commercial formulations. Published: PMC12074816 |

---

### 1.2 EVERLAST Trial

| Field | Details |
|-------|---------|
| **NCT Number** | NCT05835999 |
| **Trial Name** | EVERLAST |
| **Phase** | Phase 2 |
| **Status** | Ongoing |
| **Intervention** | Everolimus (rapalog) |
| **Key Endpoints** | Age-related functional outcomes |
| **Expected Completion** | Late 2026 |
| **Results** | Pending |

---

### 1.3 Sirolimus for Functional Decline Prevention

| Field | Details |
|-------|---------|
| **NCT Number** | NCT05237687 |
| **Phase** | Phase 2 |
| **Status** | Recruiting (2025) |
| **Intervention** | Sirolimus (rapamycin) |
| **Key Endpoints** | Prevention of age-related functional decline |
| **Results** | Pending |

---

### 1.4 Rapamycin in Alzheimer's Disease (Phase 1)

| Field | Details |
|-------|---------|
| **Publication** | Nature Communications Medicine (2025) |
| **Phase** | Phase 1 |
| **Status** | Completed |
| **Intervention** | Rapamycin |
| **Population** | Early Alzheimer's disease patients |
| **Key Endpoints** | Safety, tolerability, biomarkers of AD pathology |
| **Results** | Demonstrated safety and preliminary biomarker signals in AD patients. Published 2025. |

---

## 2. Metformin

### 2.1 TAME Trial

| Field | Details |
|-------|---------|
| **NCT Number** | Pending (funding phase) |
| **Trial Name** | TAME (Targeting Aging with Metformin) |
| **Sponsor** | American Federation for Aging Research (AFAR) / National Institute on Aging (NIA) |
| **PI** | Nir Barzilai, MD (Albert Einstein College of Medicine) |
| **Phase** | Phase 3 |
| **Status** | Recruiting / Securing final funding; now under ARPA-H framework |
| **Intervention** | Metformin extended-release 1500mg/day vs. placebo |
| **Population** | 3,000 adults aged 65-79, non-diabetic |
| **Duration** | 6 years across 14 U.S. research centers |
| **Key Endpoints** | Time to first occurrence of age-related disease (cardiovascular disease, cancer, dementia, mortality) |
| **Secondary Endpoints** | Individual disease incidence, functional decline (gait speed, grip strength), epigenetic age acceleration (GrimAge, DunedinPACE), inflammatory markers (IL-6, CRP, TNF-alpha) |
| **Results** | Not yet available |
| **Significance** | First trial with FDA agreement to use "aging" as a treatable indication; if successful, would establish a regulatory pathway for anti-aging drugs. Eli Lilly reportedly planning a TAME-like study incorporating a GLP-1 agonist. |

---

### 2.2 MILES Trial

| Field | Details |
|-------|---------|
| **NCT Number** | NCT02432287 |
| **Trial Name** | MILES (Metformin in Longevity Study) |
| **Sponsor** | Albert Einstein College of Medicine |
| **Phase** | Pilot study |
| **Status** | Completed |
| **Intervention** | Metformin |
| **Key Endpoints** | Transcriptomic and metabolomic changes consistent with aging reversal |
| **Results** | Demonstrated that metformin alters gene expression profiles in a direction consistent with younger biological age in muscle and adipose tissue. Provided molecular rationale for the TAME trial. |
| **Reference** | Barzilai N, et al. *Cell Metab*. 2016;23(6):1060-1065 |

---

## 3. Senolytics (Dasatinib + Quercetin)

### 3.1 STAMINA Study

| Field | Details |
|-------|---------|
| **Trial Name** | STAMINA |
| **Phase** | Phase 1 / Pilot |
| **Status** | Completed |
| **Intervention** | Dasatinib 100mg + Quercetin 1000mg (D+Q), intermittent dosing |
| **Population** | 12 adults with Mild Cognitive Impairment (MCI) and slow gait |
| **Duration** | 12 weeks |
| **Key Endpoints** | Safety, feasibility, senescent cell burden biomarkers |
| **Results** | Safe and feasible in MCI patients; TNF-alpha reduction correlated with MoCA score improvements; preliminary biomarker signals supporting CNS penetration of senolytic effects. |

---

### 3.2 SToMP-AD

| Field | Details |
|-------|---------|
| **NCT Number** | NCT04685590 |
| **Trial Name** | SToMP-AD (Senolytic Therapy to Modulate Progression of Alzheimer's Disease) |
| **Sponsor** | Wake Forest University; PI: Miranda Orr |
| **Phase** | Phase 2 |
| **Status** | Active |
| **Intervention** | Dasatinib 100mg + Quercetin 1000mg, 3 consecutive days every 2 weeks for 12 weeks |
| **Population** | ~20 adults aged 65+ with early-stage Alzheimer's disease |
| **Key Endpoints** | CSF senescence-associated biomarkers (p16INK4a, SASP factors), brain MRI volumetrics, cognitive assessments (ADAS-Cog, MMSE) |
| **Results** | Pending; builds on STAMINA pilot data. Interim safety data: acceptable tolerability. |
| **Reference** | Gonzales MM, et al. *Alzheimers Dement (N Y)*. 2021;7(1):e12170 (study design) |

---

### 3.3 IPF Senolytic Trial

| Field | Details |
|-------|---------|
| **Publication** | PMID: 36857968 |
| **Phase** | Phase 1 |
| **Status** | Completed |
| **Intervention** | Dasatinib + Quercetin (D+Q) |
| **Population** | Idiopathic Pulmonary Fibrosis (IPF) patients |
| **Key Endpoints** | Safety, physical function, senescent cell biomarkers |
| **Results** | Feasible and well-tolerated; preliminary improvements in physical function; reduced senescent cell markers. |
| **Reference** | Justice JN, et al. *EBioMedicine*. 2019;40:554-563 (initial); 2023 update PMID: 36857968 |

---

### 3.4 Osteoporosis D+Q Trial

| Field | Details |
|-------|---------|
| **NCT Number** | NCT06018467 |
| **Sponsor** | Odense University Hospital, Denmark |
| **Phase** | Phase 2 |
| **Status** | Active |
| **Intervention** | Dasatinib + Quercetin (D+Q) |
| **Population** | Osteoporosis patients |
| **Key Endpoints** | Bone density, bone turnover markers, senescent cell burden |
| **Results** | Pending |

---

## 4. Senolytics (Fisetin)

### 4.1 TROFFi Trial

| Field | Details |
|-------|---------|
| **Trial Name** | TROFFi |
| **Phase** | Phase 2 (RCT) |
| **Status** | Active |
| **Intervention** | Fisetin |
| **Population** | Frail breast cancer survivors |
| **Key Endpoints** | Frailty reduction, senescent cell biomarkers, quality of life |
| **Results** | Pending |
| **Reference** | ASCO 2024 abstract: JCO.2024.42.16_suppl.TPS1645 |

---

### 4.2 STOP-Sepsis

| Field | Details |
|-------|---------|
| **Trial Name** | STOP-Sepsis |
| **Phase** | Phase 2/3 |
| **Status** | Recruitment completed 2025 |
| **Intervention** | Fisetin |
| **Population** | 220 elderly patients with sepsis |
| **Key Endpoints** | Sepsis outcomes, mortality, senescent cell burden |
| **Results** | Pending; one of the larger senolytic trials to date |

---

### 4.3 Fisetin Pilot in Healthy Volunteers

| Field | Details |
|-------|---------|
| **NCT Number** | NCT06431932 |
| **Phase** | Pilot |
| **Status** | Active |
| **Intervention** | Fisetin |
| **Population** | Healthy volunteers |
| **Key Endpoints** | Safety, tolerability, pharmacokinetics, senescent cell biomarkers |
| **Results** | Pending |

---

### 4.4 Fisetin for Healthy Aging

| Field | Details |
|-------|---------|
| **NCT Number** | NCT07195318 |
| **Status** | Active/Recruiting |
| **Intervention** | Fisetin |
| **Population** | Healthy aging adults |
| **Key Endpoints** | Aging biomarkers, functional outcomes |
| **Results** | Pending |

---

### 4.5 Fisetin for Vascular Function

| Field | Details |
|-------|---------|
| **NCT Number** | NCT06133634 |
| **Status** | Active |
| **Intervention** | Fisetin |
| **Key Endpoints** | Vascular function, endothelial health, arterial stiffness |
| **Results** | Pending |

---

## 5. Senescence-Targeting Therapeutics (Other)

### 5.1 ASPIRE Trial (UBX1325)

| Field | Details |
|-------|---------|
| **Trial Name** | ASPIRE |
| **Sponsor** | Unity Biotechnology |
| **Phase** | Phase 2b |
| **Status** | Completed |
| **Intervention** | UBX1325 (foselutoclax, BCL-xL inhibitor, intravitreal injection) |
| **Population** | Diabetic Macular Edema (DME) patients |
| **Key Endpoints** | Best-corrected visual acuity (BCVA), central subfield thickness |
| **Results** | **5.6 letters improvement** in BCVA at 48 weeks from single injection; statistically significant and clinically meaningful; published in **NEJM Evidence**. No systemic thrombocytopenia. One of the strongest clinical proof points for senolytic therapy. |

---

### 5.2 Rubedo RLS-1496 -- Actinic Keratosis (US)

| Field | Details |
|-------|---------|
| **Sponsor** | Rubedo Life Sciences |
| **Phase** | Phase 1b/2a |
| **Status** | FDA IND cleared (September 2025); trial initiating |
| **Intervention** | RLS-1496 (selective GPX4 modulator, topical) |
| **Population** | Actinic keratosis patients |
| **Key Endpoints** | Safety, efficacy, senescent cell clearance |
| **Results** | Pending |

---

### 5.3 Rubedo RLS-1496 -- Psoriasis / Dermatitis / Skin Aging (EU)

| Field | Details |
|-------|---------|
| **Sponsor** | Rubedo Life Sciences |
| **Phase** | Phase 2 |
| **Status** | EMA-cleared; first patient dosed (May 2025) |
| **Intervention** | RLS-1496 (selective GPX4 modulator) |
| **Population** | Psoriasis, dermatitis, and skin aging patients |
| **Key Endpoints** | Skin condition improvement, senescent cell reduction, aging biomarkers |
| **Results** | Pending |

---

## 6. NAD+ Precursors (NR / NMN)

### 6.1 NR in Mild Cognitive Impairment

| Field | Details |
|-------|---------|
| **Publication** | PMC10828186 |
| **Phase** | Pilot |
| **Status** | Completed |
| **Intervention** | Nicotinamide Riboside (NR) |
| **Population** | Adults with Mild Cognitive Impairment (MCI) |
| **Key Endpoints** | Cognitive function, NAD+ levels, safety, epigenetic aging clocks |
| **Results** | Increased blood NAD+; well tolerated; did NOT alter cognition; modest NR-associated increase in DNA methylation; reduction in epigenetic age (PhenoAge and GrimAge). |

---

### 6.2 NR in Long-COVID

| Field | Details |
|-------|---------|
| **Publication** | Lancet eClinicalMedicine (2025) |
| **Phase** | Randomized controlled trial |
| **Status** | Completed |
| **Intervention** | Nicotinamide Riboside (NR) 2000mg/day for 24 weeks |
| **Population** | 58 Long-COVID patients |
| **Key Endpoints** | Fatigue, functional capacity, NAD+ metabolism |
| **Results** | Demonstrated benefits in Long-COVID symptomatology. Published 2025 in Lancet eClinicalMedicine. |

---

### 6.3 NADage Study

| Field | Details |
|-------|---------|
| **NCT Number** | NCT06208527 |
| **Trial Name** | NADage |
| **Status** | Active |
| **Intervention** | Nicotinamide Riboside (NR) |
| **Key Endpoints** | NAD+ levels, aging biomarkers |
| **Results** | Pending |

---

### 6.4 NMN Clinical Trial

| Field | Details |
|-------|---------|
| **NCT Number** | NCT07144527 |
| **Status** | Active/Recruiting |
| **Intervention** | Nicotinamide Mononucleotide (NMN) |
| **Key Endpoints** | NAD+ metabolism, aging biomarkers |
| **Results** | Pending |

---

### 6.5 NMN in Middle-Aged Adults

| Field | Details |
|-------|---------|
| **Publication** | GeroScience |
| **Phase** | Randomized controlled trial (multicenter) |
| **Status** | Completed |
| **Intervention** | Nicotinamide Mononucleotide (NMN) |
| **Population** | Healthy middle-aged adults |
| **Key Endpoints** | NAD+ levels, metabolic parameters, physical function |
| **Results** | Demonstrated NAD+ elevation and metabolic benefits. Published in GeroScience. |

---

## 7. Alpha-Ketoglutarate (AKG)

### 7.1 ABLE Trial

| Field | Details |
|-------|---------|
| **Trial Name** | ABLE |
| **Location** | Singapore |
| **Phase** | Phase 2 |
| **Status** | Active |
| **Intervention** | Calcium Alpha-Ketoglutarate (Ca-AKG) 1g sustained-release, 6 months + 3-month follow-up |
| **Population** | 120 adults aged 40-60 |
| **Key Endpoints** | Biological age (epigenetic clocks), functional outcomes |
| **Results** | Pending; one of the most rigorous AKG aging trials to date |

---

### 7.2 AKG Clinical Trial

| Field | Details |
|-------|---------|
| **NCT Number** | NCT05706389 |
| **Status** | Active |
| **Intervention** | Alpha-Ketoglutarate (AKG) |
| **Key Endpoints** | Aging biomarkers, metabolic parameters |
| **Results** | Pending |

---

### 7.3 Ca-AKG Evaluation

| Field | Details |
|-------|---------|
| **NCT Number** | NCT07114536 |
| **Status** | Active/Recruiting |
| **Intervention** | Calcium Alpha-Ketoglutarate (Ca-AKG) |
| **Key Endpoints** | Biological age, safety, metabolic endpoints |
| **Results** | Pending |

---

## 8. Spermidine

### 8.1 POLYCAD Trial

| Field | Details |
|-------|---------|
| **Trial Name** | POLYCAD |
| **Status** | Recruitment completed August 2025 |
| **Intervention** | Spermidine |
| **Population** | 187 elderly patients with Coronary Artery Disease (CAD) |
| **Key Endpoints** | Cardiac function, autophagy markers, cardiovascular outcomes, cardiometabolic endpoints, muscle mass |
| **Results** | Evaluating spermidine's autophagy-enhancing effects in cardiovascular disease patients |

---

## 9. Urolithin A (Mitopure)

### 9.1 MitoImmune Study

| Field | Details |
|-------|---------|
| **Trial Name** | MitoImmune |
| **Sponsor** | Amazentis/Timeline |
| **Status** | Completed |
| **Intervention** | Urolithin A (Mitopure) 1000mg/day for 4 weeks |
| **Population** | 50 adults |
| **Publication** | Nature Aging (2025) |
| **Key Endpoints** | Immune function, mitophagy, inflammation markers |
| **Results** | Significant expansion of naive CD8+ T cells, demonstrating immune rejuvenation via mitophagy activation. Published in Nature Aging 2025. |

---

### 9.2 CLARITY Study

| Field | Details |
|-------|---------|
| **Trial Name** | CLARITY |
| **Sponsor** | Amazentis/Timeline |
| **Status** | Ongoing |
| **Intervention** | Urolithin A (Mitopure) |
| **Population** | 650 participants |
| **Focus** | Brain health and mitochondrial function |
| **Key Endpoints** | Mitochondrial function, physical performance, aging biomarkers |
| **Results** | Expected **March 2026**; one of the largest controlled trials of a mitophagy enhancer |

---

## 10. Mitochondrial-Targeted Peptides

### 10.1 TAZPOWER Trial (Elamipretide)

| Field | Details |
|-------|---------|
| **Trial Name** | TAZPOWER |
| **Sponsor** | Stealth BioTherapeutics |
| **Phase** | Phase 2/3 (pivotal) |
| **Status** | Completed |
| **Intervention** | Elamipretide (SS-31, mitochondria-targeted peptide) |
| **Population** | Barth syndrome patients |
| **Key Endpoints** | Six-minute walk test, cardiac function, functional capacity |
| **Results** | Showed trends toward improvement in some functional endpoints. Contributed to FDA accelerated approval of FORZINITY (September 2025) for Barth syndrome. |

---

### 10.2 MMPOWER-3 Trial (Elamipretide)

| Field | Details |
|-------|---------|
| **Trial Name** | MMPOWER-3 |
| **Sponsor** | Stealth BioTherapeutics |
| **Phase** | Phase 3 |
| **Status** | Completed |
| **Intervention** | Elamipretide |
| **Population** | Primary mitochondrial myopathy patients |
| **Key Endpoints** | Six-minute walk test, functional endpoints |
| **Results** | Failed primary endpoint; highlighted challenges in mitochondrial disease trial design. |

---

## 11. GLP-1 Receptor Agonists (Aging-Relevant)

### 11.1 EVOKE / EVOKE+ Trials

| Field | Details |
|-------|---------|
| **Trial Name** | EVOKE and EVOKE+ |
| **Sponsor** | Novo Nordisk |
| **Phase** | Phase 3 |
| **Status** | Active |
| **Intervention** | Semaglutide (oral) |
| **Population** | Early-stage Alzheimer's disease patients |
| **Key Endpoints** | Cognitive decline (ADAS-Cog), clinical dementia rating, brain atrophy (MRI) |
| **Results** | Pending; represents a major test of the metabolic-neurodegeneration hypothesis |
| **Significance** | If positive, would establish GLP-1 agonists as a new class of anti-aging therapeutics beyond metabolic disease |

**Relevance to Aging:**
Semaglutide has demonstrated effects on epigenetic aging clocks in separate studies:
- PCGrimAge: -3.1 years
- PhenoAge: -4.9 years
- DunedinPACE: 9% slower pace of aging

---

## 12. Gene Therapy for Aging

### 12.1 Klotho + Follistatin Gene Therapy

| Field | Details |
|-------|---------|
| **Phase** | Early phase |
| **Status** | Active/Planned |
| **Intervention** | Klotho + Follistatin gene therapy (combinatorial AAV delivery) |
| **Population** | Healthy adults |
| **Key Endpoints** | Safety, gene expression, aging biomarkers |
| **Results** | Pending; represents one of the first gene therapy trials explicitly targeting aging in healthy individuals |
| **Context** | Klotho gene therapy extended mouse lifespan by 19.7% (Molecular Therapy, 2025); intranasal AAV-Follistatin extended mouse lifespan by ~30% |

---

## 13. Master Summary Table

| # | NCT Number | Trial Name | Sponsor | Phase | Status | Intervention | Indication | Key Results |
|---|-----------|------------|---------|-------|--------|--------------|------------|-------------|
| 1 | NCT04488601 | PEARL | AgelessRx | Phase 2 | Completed | Rapamycin 5/10mg weekly, 48 wks | Healthy aging (114 adults) | Lean mass improved (women); safe |
| 2 | -- | TAME | AFAR/NIA | Phase 3 | Recruiting/Funding | Metformin 1500mg/day | Aging (6 yrs, 3,000 adults) | Pending |
| 3 | -- | STAMINA | Academic | Phase 1/Pilot | Completed | D+Q | MCI (12 adults, 12 wks) | Safe; TNF-alpha reduction |
| 4 | NCT04685590 | SToMP-AD | Wake Forest | Phase 2 | Active | D+Q | Alzheimer's (~20 adults) | Pending |
| 5 | -- | IPF D+Q | Mayo Clinic | Phase 1 | Completed | D+Q | IPF (PMID: 36857968) | Improved function; tolerable |
| 6 | NCT06018467 | Osteoporosis D+Q | Odense Univ | Phase 2 | Active | D+Q | Osteoporosis | Pending |
| 7 | -- | TROFFi | Academic | Phase 2 | Active | Fisetin | Frail breast cancer survivors | Pending |
| 8 | -- | STOP-Sepsis | Academic | Phase 2/3 | Recruitment complete | Fisetin | Elderly sepsis (220 pts) | Pending |
| 9 | NCT06431932 | Fisetin Pilot | Academic | Pilot | Active | Fisetin | Healthy volunteers | Pending |
| 10 | NCT07195318 | Fisetin Aging | -- | -- | Active | Fisetin | Healthy aging | Pending |
| 11 | NCT06133634 | Fisetin Vascular | Academic | -- | Active | Fisetin | Vascular function | Pending |
| 12 | -- | ASPIRE | Unity Biotech | Phase 2b | Completed | UBX1325 (intravitreal) | DME | **+5.6 letters (NEJM Evidence)** |
| 13 | NCT05835999 | EVERLAST | -- | Phase 2 | Ongoing | Everolimus | Healthy aging | Pending (late 2026) |
| 14 | NCT05237687 | Sirolimus FD | -- | Phase 2 | Recruiting | Sirolimus | Functional decline | Pending |
| 15 | -- | NR MCI | Academic | Pilot | Completed | NR | MCI (PMC10828186) | NAD+ up; PhenoAge/GrimAge reduced; cognition unchanged |
| 16 | -- | NR Long-COVID | Academic | RCT | Completed | NR 2000mg/day, 24 wks | Long-COVID (58 pts) | Benefits (Lancet eClinMed 2025) |
| 17 | NCT06208527 | NADage | -- | -- | Active | NR | Aging biomarkers | Pending |
| 18 | NCT07144527 | NMN Trial | -- | -- | Active | NMN | NAD+ metabolism | Pending |
| 19 | -- | NMN Middle-Age | Academic | RCT | Completed | NMN | Middle-aged adults | NAD+ elevation; metabolic benefits (GeroScience) |
| 20 | NCT02432287 | MILES | Einstein | Pilot | Completed | Metformin | Aging transcriptomics | Gene expression shifts toward youth |
| 21 | -- | ABLE | Singapore | Phase 2 | Active | Ca-AKG 1g, 6 mos | Biological aging (120 adults) | Pending |
| 22 | NCT05706389 | AKG Trial | -- | -- | Active | AKG | Aging biomarkers | Pending |
| 23 | NCT07114536 | Ca-AKG Eval | -- | -- | Active | Ca-AKG | Biological age | Pending |
| 24 | -- | POLYCAD | Academic | -- | Recruitment complete | Spermidine | CAD (187 patients) | Evaluating |
| 25 | -- | MitoImmune | Amazentis | -- | Completed | Urolithin A 1000mg/day, 4 wks | Immune aging (50 adults) | **Naive CD8+ T cell expansion (Nature Aging 2025)** |
| 26 | -- | CLARITY | Amazentis | -- | Ongoing | Urolithin A | Brain health (650 pts) | Expected March 2026 |
| 27 | -- | TAZPOWER | Stealth Bio | Phase 2/3 | Completed | Elamipretide | Barth syndrome | Trends toward benefit; contributed to FDA approval |
| 28 | -- | MMPOWER-3 | Stealth Bio | Phase 3 | Completed | Elamipretide | Mito myopathy | Failed primary endpoint |
| 29 | -- | Rapamycin AD | Academic | Phase 1 | Completed | Rapamycin | Alzheimer's | Safe; biomarker signals (Nat Comms Med 2025) |
| 30 | Multiple | EVOKE/EVOKE+ | Novo Nordisk | Phase 3 | Active | Semaglutide (oral) | Alzheimer's | Pending |
| 31 | -- | Rubedo AK (US) | Rubedo | Phase 1b/2a | IND cleared Sept 2025 | RLS-1496 (GPX4 mod) | Actinic keratosis | Starting |
| 32 | -- | Rubedo EU | Rubedo | Phase 2 | First dosed May 2025 | RLS-1496 | Psoriasis/dermatitis/skin aging | Pending |
| 33 | -- | Gene Therapy | -- | Early | Active | Klotho + Follistatin | Healthy adults | Pending |

---

## Trial Landscape Analysis

### By Intervention Class

| Intervention Class | Total Trials | Completed | Active/Ongoing | Key Findings |
|-------------------|-------------|-----------|----------------|-------------|
| mTOR Inhibitors | 4 | 2 | 2 | Lean mass benefits (PEARL); safe in AD (Phase 1) |
| Metformin | 2 | 1 | 1 | MILES: gene expression shifts; TAME: landmark trial pending |
| Senolytics (D+Q) | 4 | 2 | 2 | Feasible in MCI and IPF; expanding to AD and osteoporosis |
| Senolytics (Fisetin) | 5 | 0 | 5 | Large pipeline; STOP-Sepsis (n=220) is largest |
| Senescence Drugs (Other) | 3 | 1 | 2 | ASPIRE: +5.6 letters (strongest clinical proof point) |
| NAD+ Precursors | 5 | 3 | 2 | Consistent NAD+ elevation; Long-COVID benefits; modest epigenetic clock effects |
| AKG | 3 | 0 | 3 | All active; Singapore ABLE trial (n=120) is most rigorous |
| Spermidine | 1 | 0 | 1 | POLYCAD: cardiovascular application (n=187) |
| Urolithin A | 2 | 1 | 1 | Nature Aging publication; CLARITY (n=650) pending |
| Mito Peptides | 2 | 2 | 0 | Mixed results; FORZINITY FDA approval for Barth |
| GLP-1 Agonists | 1 | 0 | 1 | EVOKE/EVOKE+: high-impact if positive |
| Gene Therapy | 1 | 0 | 1 | Klotho+Follistatin: first-in-kind for aging |

### By Phase

| Phase | Count |
|-------|-------|
| Pilot/Phase 1 | 9 |
| Phase 2 | 14 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |
| Unspecified/Other | 5 |

### Key Observations

1. **Senolytics dominate the pipeline**: 12 of 33 trials (36%) involve senolytic interventions (D+Q, fisetin, UBX1325, RLS-1496), reflecting the maturity of the senescence hypothesis.

2. **NAD+ precursors generate consistent biochemical data**: With 3 completed trials showing consistent NAD+ elevation, NR and NMN reliably raise NAD+ levels. However, clinical endpoint improvements remain inconsistent -- the "NAD+ paradox."

3. **TAME remains the field's flagship**: If the TAME trial succeeds, it would establish the first FDA-recognized pathway for treating "aging" as an indication, potentially transforming the regulatory landscape.

4. **Ocular indications are a proving ground**: Multiple trials (ASPIRE for DME, Life Bio for eye) target ophthalmic conditions, which offer accessible endpoints and local delivery.

5. **GLP-1 agonists are the dark horse**: The EVOKE/EVOKE+ trials, combined with epigenetic clock data showing age reversal with semaglutide, could reframe GLP-1 agonists as anti-aging drugs.

6. **Gene therapy for aging is nascent**: Only one trial (Klotho+Follistatin) explicitly targets aging in healthy adults, representing a paradigm shift from treating disease to enhancing health.

7. **Epigenetic clocks as endpoints**: Growing adoption of DunedinPACE, GrimAge, and PhenoAge as clinical trial endpoints is standardizing how aging interventions are measured.

8. **Dermatology as accelerated entry point**: Rubedo's RLS-1496 trials in actinic keratosis and skin aging provide well-defined clinical endpoints and faster regulatory timelines for senescence-targeting drugs.

---

*This document is a research compilation for informational purposes. Clinical trial details are based on publicly available information, ClinicalTrials.gov registrations, and published literature as of February 2025.*
